siltartoxatug

**Siltartoxatug** is a first-in-class recombinant, fully human monoclonal antibody targeting tetanus toxin for post-exposure prophylaxis of tetanus. Developed using Trinomab's HitmAb antibody discovery platform, it neutralizes tetanus neurotoxin produced by Clostridium tetani, thus preventing the development of clinical tetanus in exposed individuals. Unlike traditional passive immunization agents—plasma-derived human tetanus immunoglobulin (HTIG) or equine tetanus antitoxin—siltartoxatug is produced via genetic engineering and avoids the risks of blood-product contamination and allergic reactions. It is administered as a single intramuscular injection in adults. In a randomized phase 3 trial, siltartoxatug achieved higher and longer-lasting anti-tetanus neutralizing antibody titers more rapidly than HTIG, with a favorable safety profile. It was approved for marketing in China in February 2025 for urgent tetanus prophylaxis in adults[1][2][3][5][7].

Brand names

Sintetol新替妥

Other names

siltartoxatug injection